CompletedPhase 3ACTRN12611000865910

A Phase III Randomised, Double-blind, Placebo-controlled Trial to Assess the Efficacy of Tranexamic Acid in Reducing the Blood Loss in Patients with Per-rectal Bleeding

A Phase III Randomised, Double-blind, Placebo-controlled Pragmatic Trial to Assess the Efficacy of Tranexamic Acid in Reducing the Blood Loss in Patients with Per-rectal Bleeding

Sponsor

John Hunter Hospital

Enrollment

100 participants

Start Date

Nov 9, 2011

Study Type

Interventional

Conditions

lower gastrointestinal bleeding

Summary

A study to assess the effectiveness of oral tranexamic acid to placebo in reducing the amount of blood loss from lower gastrointestinal bleeding, and to reduce the amount of blood needed to be transfused.

Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This trial tests whether tranexamic acid (a blood-clotting medication taken by mouth) can reduce blood loss in patients with rectal bleeding. Eligible participants are adults aged 18+ who can swallow the study medication. People with a history of blood clots, those on blood thinners, pregnant women, and those with known bowel cancer are excluded.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Tranexamic acid 1000mg taken orally every 6 hours for 4 days.

Locations(1)

John Hunter Hospital Royal Newcastle Centre - New Lambton

NSW, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12611000865910